linjc16/ctgov huggingface dataset:
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Study Overview
=================
Brief Summary
-----------------
This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.

Official Title
-----------------
A Continuation Study Of PF-3512676 (CPG 7909) Injection In Patients With Metastatic Or Recurrent Malignancies Who Have Stable Disease Or Who Have Responded To Pf-3512676 Injection Therapy

Conditions
-----------------
Melanoma, Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, T-Cell, Carcinoma, Non-Small-Cell Lung

Intervention / Treatment
-----------------
* Drug: PF-3512676


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Immediate (within 4 weeks) prior completion of a clinical trial of PF-3512676 Injection alone or in combination with other anti-neoplastic treatment for malignancy. Exclusion Criteria: The patient has received any anti-neoplastic therapy since completing a prior trial with PF-3512676 Injection, or has participated in another clinical trial following participation in a trial with PF-3512676 Injection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley. | Drug: PF-3512676<br>* PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.<br>* Other names: CPG 7909, ProMune;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Events and DLTs will be evaluated by the Investigator and summarized. |  | indeterminate | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| No formal statistical analysis of this study will be conducted. All clinical data may be summarized and included in data listings. |  | indeterminate | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CPG 7909 continuation study
Incidence of Commuting Accidents Among Non-physician Staff of a Large University Hospital Center From 2012 to 2016

Study Overview
=================
Brief Summary
-----------------
Over the past thirty years, risk of road traffic accidents has decreased but remains high and accounts for 44% of fatal work-related accidents for commuting and mission-related accidents. The aims of this study were to estimate the overall incidence of commuting accidents for non-physician professionals in a major university hospital and by gender and different professional categories, and to assess its evolution over a 5-year period. A descriptive analysis was performed on 390 commuting accidents from 2012 to 2016 extracted from the university hospital's occupational health service.

Official Title
-----------------
Incidence of Commuting Accidents Among Non-physician Staff of a Large University Hospital Center From 2012 to 2016

Conditions
-----------------
Accident, Traffic

Intervention / Treatment
-----------------
* Other: Characteristics of accidents


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: non-physician staff commuting accidents Exclusion Criteria: work accidents on-duty road accidents physician staff
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non-physician staff<br>All non-physician staff who have had commuting accidents | Other: Characteristics of accidents<br>* informations about commuting accidents were recorded either during an occupational medicine consultation or by the medical service after reception of the medical certificate and the administrative declaration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of commuting accidents | Incidence of commuting accidents according to sex, occupational categories and year of accident. The evolution of the number of accidents over the years was assessed by the Cochran-Armitage Chi² trend test. Crude Relative risk (RR) and 95% confidence intervals for the association of commuting accident with respectively sex, occupational categories and years were estimated on log-binomial regression using the using the GENMOD procedure in the SAS statistical package (version 9.4) with the DIST=BINOMIAL and LINK=LOG options. | at the enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Commuting accident, Traffic accident, Hospital, Descriptive study, Incidence, Health care worker
A Feasibility Study to Assess Pre Admission Status and Six Month Outcomes After Major Trauma

Study Overview
=================
Brief Summary
-----------------
This study aims to assess the feasibility of obtaining details about a patients previous level of function from the patient of friend/relative, after they have been admitted an intensive care unit (ICU). It will also assess the feasibility of re-assessing level of function at 6 months after the patient has been discharged from ICU.

Detailed Description
-----------------
Currently there is no standardised way of obtaining details about a patients pre-admission level of function. the process of gaining this history is often done by several different people with no standard questions asked. There is also a need to be able to measure what happens to patients after they leave ICU, and compare their abilities to preadmission status. This feasibility study will aim to investigate: the time taken to train the physiotherapy team in the use of the outcome measure the ability to obtain pre admission functional status from patients/friend/relative on admission to ICU the ability to follow patients up at 6 months post discharge with re-assessment of the outcome measure

Official Title
-----------------
A Feasibility Study to Assess Pre Admission Status and Six Month Outcomes of Major Trauma Patients Admitted to an Intensive Care Unit, Using the WHO DAS 2.0.

Conditions
-----------------
Multiple Trauma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant is willing and able to give informed consent for participation in the study Participants relative or friend (consultee) is willing and able to give informed consent for participation in the study (where the patient is unable to give informed consent) Male or Female, aged 18 years or above Injury Severity Score greater than 9 Admitted as an emergency to AICU Experienced at least 24 hours level three care during their admission Exclusion Criteria: Non UK resident (due to potential loss to follow up) Unwilling to consent No GP details available Patients with a palliative diagnosis or established on a palliative treatment pathway

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| WHODAS 2.0 completion rate | Number of questionnaires completed/returned on admission to ICU | 2 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to questionnaire completion rate | The time taken (hours) from ICU admission to complete the questionnaire | 2 days | 
| WHODAS 2.0 completion rate | Number of questionnaires completed/returned at 6 months post ICU discharge | 6 months post ICU discharge |
Crocin Supplementation in CSCR

Study Overview
=================
Brief Summary
-----------------
Preclinical and clinical evidence support the protective effect of crocin on different pathologic pathways involved in central serous chorioretinopathy (CSCR). They involve inflammation, oxidative stress, mineralocorticoid pathway, and also stress-related injuries. It also showed that crocin has a protective effect on the retinal pigmented epithelium (RPE) layer. Based on the mentioned evidence the study designed to evaluate the efficacy and safety of 2-month crocin supplementation (15 mg/d) in 40 patients with CSCR in a randomized controlled blinded clinical trial.

Official Title
-----------------
Efficacy and Safety of Crocin Supplementation in Patients With Central Serous Chorioretinopathy (CSCR)

Conditions
-----------------
Chorioretinopathy, Central Serous

Intervention / Treatment
-----------------
* Drug: Crocin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age of 18-60 years old The diagnosis of CSCR based on clinical and imagining evaluation informed consent Exclusion Criteria: Chronic CSCR Laser treatment (6 months prior to enrollment) IVB treatment (3 months prior to enrollment) Other retinal diseases History of eye diseases Diabetes Mellitus Renal or hepatic diseases Allergy to saffron or crocin Pregnancy or lactation Beta-blocker, diuretic, or corticosteroid (1 week prior to enrollment) Bleeding tendency or any coagulation disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Crocin<br> | Drug: Crocin<br>* 15 mg/d<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* 15 mg/d<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best-corrected visual acuity (BCVA) |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Foveal thickness (μm) | measured by OCT imaging | 8 weeks | 
| Subretinal fluid height (μm) | measured by OCT imaging | 8 weeks | 
| Subfoveal choroidal thickness (μm) | measured by OCT imaging | 8 weeks | 
| Number of participants need to laser therapy | based on clinical criteria | 8 weeks | 
| Total number of reported adverse events | based on patients reported adverse events | 8 weeks |
Prokinecitine in Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
The study aims to investigate the presence of a substance in the blood called prokinecitine, which is released by the heart when a heart attack occurs. Several venous blood samples at the arm are withdrawn at admission, H6, H12, H24, H48 and H72 in order to measure the concentration of this substance in the blood. The usefulness of this new blood marker is going to be determsined to seek if it would be of help to better diagnose or estimate the gravity of heart infarction after a heart attack.

Official Title
-----------------
Pilot Study Prok-Idm: Interest of Dosage of Prokinecitine in Acute Myocardial Infarction

Conditions
-----------------
ST Elevatation Myocardial Infarction (STEMI)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with acute St elevation myocardial infarction of less than 6 hours Age>18 y/o Exclusion Criteria: Previous myocardial infarction LBB, RBB Renal Insuffiency MDRD<30 mL/min Patient with Pace-Maker or ICD.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infarct size by MRI necrotic myocardial mass | Infarct size by MRI necrotic myocardial mass | 7 days |
Effects of Home-based Resistance Exercise on Body Composition, Muscle Strength and Glycemic Control in People With Type 2 Diabetes.

Study Overview
=================
Brief Summary
-----------------
This study investigates the effects of home-based resistance exercise training, compared to a control group, on body composition, muscle strength and glycaemic control in people with type 2 diabetes. Half participants will be in the home-based exercise group and half in the control group.

Official Title
-----------------
Effects of Home-based Resistance Exercise on Body Composition, Muscle Strength and Glycemic Control in People With Type 2 Diabetes.

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Behavioral: Home-based


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Physician diagnosed type 2 diabetes No changes in anti-diabetic medication in the last 3 months Exclusion Criteria: Not currently or in the past year participating in any vigorous aerobic activity (>1h per week) or any resistance exercise. BMI of 45 or higher Blood pressure of 160/100mmHg or higher Currently receiving insulin therapy

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>Usual Care | |
| Active Comparator: Home-based<br>Home-based resistance exercise training | Behavioral: Home-based<br>* Resistance exercise carried out unsupervised at home<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycated Haemoglobin concentration (mmol/mol) | Glycated haemaglobin | Change from baseline to 32 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fat-free mass | Whole body fat free mass | Change from baseline to 32 weeks | 
| Short performance physical battery test | Short performance physical battery test (0 (worst performance) to 12 (best performance)) | Change from baseline to 32 weeks |
Development and Application of Virtual Reality (VR) and Human Computer Interaction System in the ICU Patients

Study Overview
=================
Brief Summary
-----------------
By developing of VR and human computer interaction system of early rehabilitation exercise for ICU patients, this project aims to construct virtual scenes and realize the interaction between ICU patients and virtual scenes during active rehabilitation training for critically ill patients in long-term bed. This project can increase the patient's willingness to exercise rehabilitation, improve the training effect and improve clinical outcomes in critically ill patients.

Official Title
-----------------
Virtual Reality (VR) and Human Computer Interaction System in the Early Stage of ICU Patients Development and Application of Rehabilitation Exercise

Conditions
-----------------
Rehabilitation Exercise of ICU Patients

Intervention / Treatment
-----------------
* Behavioral: Virtual Reality (VR) and human computer interaction system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18 years of age Voluntary participation Exclusion Criteria: Unable to walk independently before admission to ICU; High dose of vasoactive drugs to maintain vital signs; Acute stroke; Upper limb fractures or amputations; Patients with spinal fracture or pathological fracture; Patients who have been hospitalized for 30 days or more before admission to ICU; Plan to move out of ICU within 24 hours; In palliative care

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intervention group<br> | Behavioral: Virtual Reality (VR) and human computer interaction system<br>* The experimental group used VR technology and human-computer interaction system for exercise, while the control group used traditional exercise program<br>|
| No Intervention: control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of the ICU-acquired asthenia | during ICU stay | up to 2 weeks | 
| Average daily physical activity time | during ICU stay | up to 2 weeks | 
| length of ICU stay | during ICU stay | up to 2 weeks |
Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women

Study Overview
=================
Brief Summary
-----------------
Iron deficiency is the most prevalent nutritional deficiency and the most common cause of anemia .It is characterized by a defect in hemoglobin synthesis, resulting in red blood cells that are abnormally small (microcytic) and contain a decreased amount of hemoglobin (hypochromic).

Official Title
-----------------
Total Dose Infusion of Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women: a Randomized Controlled Trial

Conditions
-----------------
Anemia

Intervention / Treatment
-----------------
* Drug: Iron dextran
* Drug: Ferrous Fumarate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hemoglobin < 10 g/dL Gestational age between 14-28 weeks. Willingness to participate and signing the informed consent form. Exclusion Criteria: Iron overload or disturbances in utilization of iron Decompensated liver cirrhosis and active hepatitis Active acute or chronic infections History of multiple allergies Known hypersensitivity to parenteral iron or any recipients in the investigation drug products Erythropoietin treatment within 8 weeks prior to the screening visit Other iron treatment or blood transfusion within 4 weeks prior to the screening visit Planned elective surgery during the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intravenous iron<br>patients will receive intravenous iron as total dose infusion | Drug: Iron dextran<br>* total dose infusion<br>|
| Active Comparator: oral iron<br>patients will receive oral iron | Drug: Ferrous Fumarate<br>* oral tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change in Hemoglobin concentration from baseline to 8 weeks therapy | measure hemoglobin level before and after treatment | 8 weeks |
Surgeons' Satisfaction With the Surgical Training Program in Egypt

Study Overview
=================
Brief Summary
-----------------
In Egypt, the evidence for quality processes has not been established yet in the current training programs for surgery residents. There are no published articles discussing career satisfaction among surgical residents. Therefore, we are going to conduct a self-designed survey in Egyptian university hospitals to measure residents' satisfaction and display views about their undergraduate surgical education, surgical education during internship year, post-graduate training program, and extracurricular activity during medical school.

Official Title
-----------------
Young Surgeons' Satisfaction With the Surgical Training Program in Egyptian University Hospitals: A Multi-center Cross-sectional Study

Conditions
-----------------
Satisfaction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: We will include the Egyptian academic surgeons, within their first 8 years after their graduation. We will include surgeons in general surgery and other surgery subspecialties such as orthopedic surgery, neurosurgery, urology, and plastic surgery Exclusion Criteria: We will exclude surgeons who received part of their training program abroad.

Ages Eligible for Study
-----------------
Minimum Age: 26 Years
Maximum Age: 34 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Surgeons<br>Young surgeons in all surgical specialities | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgeons' satisfaction with undergraduate surgical education, surgical training during the internship year, and residency using validated questionnaire | By validated questionnaire, we will assess surgeons' satisfaction with lectures, clinical rounds, skill labs during undergraduate, satisfaction with tutorials, operating room, outpatient clinic, ward rounds, and seminars during internship year, satisfaction with theoretical and clinical training program, and number of working hours during the residency. | Within 8 years of graduation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Define the reasons of dissatisfaction by validated questionnaire. | Using validated questionnaire, we will assess the reasons of dissatisfaction such as insufficient teaching time, dysfunctional curriculum, training environment, and teaching methodology. | Within 8 years of graduation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Satisfaction, Training program, Egypt, Cross-sectional, Multi-center